ReviewAnnals of hematology2026
De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hereditary spherocytosis (HS) is characterized primarily by jaundice, anemia, splenomegaly (enlarged spleen), increased numbers of spherocytes in peripheral blood, and elevated erythrocyte osmotic fragility. However, these manifestations are nonspecific, resulting in misdiagnosis or underdiagnosis. Here, we report three Chinese patients with a family history of HS. Case 1 was an infant who presented with jaundice and anemia during the neonatal period, without splenomegaly; case 2 was a woman with hepatitis C and mild anemia; and case 3 was a child with no obvious clinical symptoms. Genetic testing revealed a heterozygous ANK1 c.4429 C > T (p.Arg1477*) de novo mutation in case 1, a heterozygous ANK1 c.1025_1028dup (p.Val344Profs*13) de novo mutation in case 2, and a heterozygous SPTB c.5898 C > T (p.Gly1966 =) de novo variant in case 3. Interestingly, to the best of our knowledge, the ANK1 c.4429 C > T (p.Arg1477*) and c.1025_1028dup (p.Val344Profs*13) de novo mutations have not been previously reported in public mutation databases, extending the mutation spectrum of ANK1. Overall, HS should be considered in patients with unexplained jaundice or anemia, even in those without a family history. Clinicians should conduct genetic testing to establish a definitive diagnosis, guide treatment modalities, and provide genetic counseling to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.